Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,276 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

NCT01393626
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
73
States / cities
Anaheim, California • Oceanside, California • Poway, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects

NCT00499538
View directory record Official record
Conditions
Healthy
Interventions
SKI-606
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 1 Interventional

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

NCT00637338
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-04603629, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2009 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

NCT04690855
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Talazoparib, Atezolizumab, Radiation
Drug · Radiation
Lead sponsor
Mylin A. Torres, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 27, 2026, 1:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

NCT01429740
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-05180999, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of PH-797804 on QTc Interval

NCT01862887
View directory record Official record
Conditions
Healthy
Interventions
PH-797804, Moxifloxacin, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

NCT00926263
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CP-751,871, CP-751,871, moxifloxacin, saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 27, 2026, 1:29 PM EDT
Completed No phase listed Observational Results available

Acromegaly Treatment Quality of Life Study

NCT01732406
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 1 Interventional

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 3 Interventional

Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

NCT00240747
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Synercid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
27 Weeks to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
6
States / cities
Oakland, California • Orange, California • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 2 Interventional Results available

Sunitinib and Capecitabine for First Line Colon Cancer

NCT00961571
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
sunitinib and capecitabine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 27, 2026, 1:29 PM EDT
Recruiting Phase 2 Interventional

Etrasimod as Prevention of Pouchitis

NCT07486921
View directory record Official record
Conditions
Pouchitis
Interventions
etrasimod, Placebo
Drug
Lead sponsor
Maia Kayal
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

NCT00976404
View directory record Official record
Conditions
HIV Infection
Interventions
DNA + HIV-rAd5 vaccine, ART intensification (raltegravir), ART intensification (maraviroc)
Biological · Drug
Lead sponsor
Robert L. Murphy
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 2 Interventional

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SRA-333
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 3 Interventional Results available

Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

NCT00479258
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

NCT01543087
View directory record Official record
Conditions
Meningococcal Infection
Interventions
blood sampling, bivalent rLP2086
Procedure · Drug
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 18 Years
Enrollment
698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
36
States / cities
Chandler, Arizona • Huntington Beach, California • Paramount, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00318214
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094, Vehicle gel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 27, 2026, 1:29 PM EDT
Terminated Phase 1 Interventional

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

NCT00088647
View directory record Official record
Conditions
Neoplasms
Interventions
MST-997
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 8, 2006 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

NCT05206604
View directory record Official record
Conditions
Healthy
Interventions
PF-07295324, PF-07259955
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain

NCT01216163
View directory record Official record
Conditions
Pain
Interventions
Novel Ibuprofen, Acetaminophen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 40 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 3 Interventional Results available

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

NCT01942135
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 27, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

NCT04018274
View directory record Official record
Conditions
Healthy
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 27, 2026, 1:29 PM EDT